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disease progression and development of drug resistance, 
we also know that an individual has the best chance 
of attaining long-term treatment success by starting 
treatment as soon as possible after diagnosis when CD4 
concentrations are high.9 Therefore, the identiﬁ cation 
of individuals as HIV positive as eﬃ  ciently and as soon 
as possible is important; WHO has recently introduced 
a strategy termed 90-90-90 that seeks to identify 90% 
of people in the world who are HIV positive, to treat 
90% of such people, and to attain a non-detectable viral 
load in 90% of such cases after treatment initiation. The 
hope is that this will also serve to prevent onward HIV 
transmission because individuals who have undetectable 
viraemia are unlikely to be infectious for their partners.10–12
Of course, the success of the WHO 90-90-90 guide-
lines depends on convincing a very high proportion of 
high-risk individuals who are unaware of their HIV status 
to agree to be tested. In this context, a sound argument 
can be made that more eﬀ ective incentivisation is 
urgently needed and perhaps a ﬁ nancial oﬀ ering 
could make a diﬀ erence. Although the costs of such 
a programme could be high, these would almost 
certainly be dwarfed by the costs involved in providing 
antiretroviral treatment to people who might become 
infected by those who have not yet undergone therapy 
because their HIV status is unknown.
Altogether, the results of this study are a reminder that 
the problems of HIV drug resistance and transmitted 
drug resistance are very real, especially in developing 
country settings, and that there is a need for enhanced, 
cost-eﬀ ective tests that can screen for drug resistance 
in parts of the world in which such tests are often not 
aﬀ ordable as well as for more eﬀ ective screening for HIV 
infection in the ﬁ rst place.
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Mounting evidence for use of artemisinin derivatives for 
malaria in early pregnancy
Malaria in pregnancy can be a clinically devastating con-
dition, and exacts substantial morbidity and mortality 
in vulnerable populations particularly in the developing 
world.1 Its complications are conspicuous in pregnant 
women who are prone to severe anaemia, and their 
oﬀ spring face possibilities of still births, miscarriages, or 
low birthweight.2 
To prevent malaria in pregnancy and its 
complications, various measures to reduce human–
malaria vector contact such as the use of insecticide-
treated nets and insecticide residual spraying 
are applied extensively. Chemoprevention with 
sulfadoxine–pyrimethamine is used to mitigate 
adverse pregnancy outcomes, but is also largely 
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compromised by resistance.3 Furthermore, these 
measures are not foolproof in that acquisition of 
malaria still occurs. Therefore, chemotherapy is 
imperative to eliminate the infection and prevent 
complications. 
Many endemic countries now recommend artemi-
sinin-based combinations as ﬁ rst-line treatment of 
malaria in the general population.4 Therefore, their 
widespread use makes inadvertent exposure in early 
pregnancy inevitable.5  
Although substantial information has accumulated 
to support the safe use of certain artemisinin 
derivatives as the most appropriate drugs for 
treatment of malaria in the second and third 
trimesters of pregnancy, more evidence is needed to 
support their safe use in the ﬁ rst trimester. Concerns 
about embrotoxicity and possible teratogenicity have 
led to extreme caution about the use of artemisinin 
derivatives in early pregnancy.6 The general 
recommendation is to use artemisinins only when the 
beneﬁ ts outweigh the consequences of the infection. 
To that eﬀ ect, clinical trials of artemisinin derivatives 
in early pregnancy have been slow in coming, because 
extreme caution is required to avoid untoward 
outcomes or missing out subtle damages that might 
be caused by the drugs.7
Systematic information about the safety of 
artemisinin derivatives in the early pregnancy comes 
from observational studies including pregnancy 
registries, particularly in situations where the drugs 
are taken inadvertently.5 Such studies have many 
limitations including absence of rigor to estimate 
the period and duration of exposure and inability to 
account for confounding factors or to detect subtle and 
long-term adverse outcomes in the oﬀ spring.7
In The Lancet Infectious Disease, Kerryn A Moore 
and colleagues8 report a large study describing 
a prospective observation of 2558 women with 
first-trimester malaria and analyses of 183 with 
initial exposure to various artemisinin derivatives. 
The study gives more precise details than previous 
studies about exposure to quinine and the available 
artemisinin derivatives, their doses, and the duration 
of exposure. The study affirms the association 
between infection with either vivax or falciparum 
malaria and miscarriages, and underscores the 
importance of treatment with efficacious drugs such 
as artemisinins in the first trimester to avoid adverse 
outcomes.9 The investigators uniquely estimate the 
gestation period of exposure (including the embryo-
sensitive period) to the artemisinin derivatives, 
and by use of so-called left truncation they have 
accounted for confounding from other causes of 
miscarriages.10 This study, in our view, presents a 
unique and innovative approach to the generation 
of rigorous evidence for safety of artemisinin 
derivatives when used in early pregnancy.
Although recent studies have shown encouraging 
results from some artemisinin derivatives, more 
data are still needed to ascertain the safety of 
many other artemisinin derivatives in pregnancy. 
For example, there is mounting evidence about 
the use of artemether–lumefantrine, but more 
safety information is needed on such drugs as 
dihydroartemisinin–piperaquine, which is highly 
eﬃ  cacious, has a simple treatment regimen, and has 
a relatively long protective period following intake—
an attribute that should be of important, especially in 
areas of high transmission.11 
Similar to other drugs under observation, artemisinin-
based combinations need to be subjected to intense 
pharmacovigilance to ensure that subtle anomalies or 
genetically related eﬀ ects, some of which might manifest 
in the long term, are identiﬁ ed and documented.7 Genetic 
diﬀ erences in the metabolism of various components 
of the derivatives are still a concern, so studies in diverse 
populations are needed to generate information across 
diﬀ erent ethnic groups.
With this strong evidence from this study, large 
randomised trials are justiﬁ ed to be undertaken at this 
stage to investigate other eﬀ ects that might not have 
been shown in study designs reported previously. The 
study further shows that artemisinins are as safe as 
quinine, and can be used safely in the ﬁ rst trimester. It 
has made a strong case to support the acceleration of 
the processes for recommending the use of artemisinin 
derivatives for treating malaria during the whole period 
of pregnancy. 
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Estimations of cutaneous leishmaniasis burden: 
a constant challenge  
Leishmaniases has the ninth largest diseases burden 
among the 13 parasitic and bacterial neglected tropical 
diseases.1–3 Knowledge of these diseases is poor, 
information on their global occurrence is disparate 
and sparse, and their actual burden remains uncertain.4 
Establishing the burden of cutaneous leishmaniasis is 
challenging because of the diﬃ  culty of extrapolation 
from oﬃ  cial data sources. 
In The Lancet Infectious Diseases, Chante Karimkhani 
and colleagues5 report the burden of cutaneous leish-
maniasis in 152 countries and assess the distribution 
of cutaneous leishmaniasis burden across diﬀ erent 
regions. Andean Latin America, North Africa and 
Middle East, western sub-Saharan Africa, and south 
Asia had the most disability-adjusted life-years lost 
to leishmaniasis. Also, among the 20 countries with 
the highest incidence rates worldwide, 14 are in these 
regions. The burden of leishmaniasis in these regions 
is most likely a consequence of both biotic (including 
the presence of sandﬂ ies and mammals) and abiotic 
factors (eg, land surface temperature, normalised 
diﬀ erence vegetation index, and precipitation) 
enabling stable transmission in these regions.6 
Environmental and socioeconomic factors might also 
aﬀ ect the distribution of cutaneous leish maniasis. 
An estimated 1·71 billion people live in areas where 
environmental factors potentially predispose people 
to cutaneous leishmaniasis.7 Furthermore, burden of 
leishmaniasis disproportionately aﬀ ects the poorest 
people. Poor housing conditions, environmental 
sanitation, and lack of personal protective measures 
lead to an increase of risk of infection in such 
populations.8 Karimkhani and colleagues’5 analysis of 
country-level data shows the unequal distribution of 
disease burden—mostly related to urbanisation. Other 
factors could also explain this inequality, including the 
presence of control measures focused on cutaneous 
leishmaniasis, popu lation awareness, and climate 
change. A strong association has been reported 
between climate factors (temperature, relative 
humidity, rainfall, and evaporation) and monthly 
incidence of zoonotic cutaneous leishmaniasis in 
Golestan Province, Iran.9
Since the 1993 World Development Report, policy 
makers have used disability-adjusted life-years lost 
to estimate disease burden—now the most widely 
used measure of disease burden.10,11 Nevertheless, 
the accuracy disability-adjusted life-years depends 
on the reliability of incidence estimates. Indeed, the 
main hindrance of epidemiological investigation 
is underestimation of incidence, linked to under-
reporting. In Guatemala and Jordan, the incidence 
of cutaneous leishmaniasis has been reported 
to be underestimated by 40–47-fold in national 
surveillance data.12,13 Such limitations led Karimkhani 
and colleagues to use a correction factor for under-
reporting to estimate prevalence and incidence. 
Because of the uncertainties inherent in available 
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